Mustang Bio, Inc. 2025 Annual Meeting of Stockholders and Agreement Termination

Mustang Bio, Inc. held its 2025 Annual Meeting of Stockholders on December 22, 2025, where four proposals were approved: the election of seven directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, an amendment to the 2019 Employee Stock Purchase Plan (ESPP) to increase issuable shares by 250,000 and shares subject to a Purchase Right to 10,000, and an amendment to the 2016 Incentive Plan (EIP) to increase issuable shares by 2,500,000. A quorum was present, with approximately 58% of all votes represented. Additionally, on December 17, 2025, Mustang Bio entered into a Termination and Release Agreement with Fred Hutchinson Cancer Center, terminating the CD20 License Agreement. Mustang Bio will pay $730,000 to extinguish approximately $1.4 million in payables. Fred Hutch will pay Mustang Bio at least 10% of any future consideration received from licensing the CD20 patents to a third party within three years.